Publications by authors named "Abby Van Voorhees"
Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in obese patients. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
View Article and Find Full Text PDFArticle Synopsis
- Psoriatic patients receiving vaccines need clear guidelines on whether to pause or maintain their systemic medications, especially for live and nonlive vaccines.
- The National Psoriasis Foundation Medical Board and experts developed 22 consensus statements recommending that most patients can continue oral and biologic therapies for nonlive vaccines, but should consider stopping methotrexate.
- For live vaccines, most therapies should be interrupted before and after vaccination, except for abatacept, and timing adjustments for vaccine administration are crucial.
Article Synopsis
- * Using validated screening tools for related conditions, like psoriatic arthritis, can help improve access to specialists and reduce delays in diagnosis and treatment.
- * While telehealth offers convenience and may enhance care, it should complement, not completely replace, traditional in-person dermatology or rheumatology visits.
Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.
J Psoriasis Psoriatic Arthritis
January 2023
Article Synopsis
- * Among 2,924 patients, those with obesity had a 17% and those with diabetes had a 20% rate of discontinuing treatment within 6 months, which was higher than those without these conditions.
- * The findings suggest that assessing comorbidities, particularly obesity and diabetes, at the start of biologic treatment could help predict treatment success and improve management of psoriasis.
Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry.
J Psoriasis Psoriatic Arthritis
July 2022
: How psoriasis disease characteristics, management, and outcomes each vary across the US is not fully understood. : Assess regional disease characteristics for patients enrolled in CorEvitas Psoriasis Registry, report biologic initiations by class over the period, and evaluate regional outcome data for initiations with 6-month follow-up. : Participants included new biologic initiations in CorEvitas Psoriasis Registry from 2014-2019 categorized into 7 different geographic regions: Northeast, East North Central, Mountain/West North Central, South Atlantic, East South Central, West South Central, and Pacific.
View Article and Find Full Text PDFBackground: Associations between cardiometabolic multimorbidity and response to therapy in psoriasis are unknown.
Objective: Determine the associations of multimorbidity with response to biologic treatment in psoriasis patients.
Methods: CorEvitas Psoriasis Registry participants who initiated biologic therapy and had 6-month follow-up were stratified by 0, 1, 2+ comorbidities (diabetes, hypertension, hyperlipidemia).
Studies have shown that subjects with psoriasis (PsO) are associated with an increased risk of developing metabolic syndrome (MetS), diabetes, and cardiovascular disease. In addition, MetS and diabetes are associated with autonomic dysfunction (AD). The aim of this study was to investigate cardiac and sudomotor autonomic function in subjects with PsO and without diabetes.
View Article and Find Full Text PDFLittle is known about how psoriatic disease characteristics and treatment outcomes differ geographically in the United States. Our aim was to explore real-world, geographic variations in the use of biologic classes and outcomes within the Corrona Psoriasis Registry. Patient demographics and disease characteristics were assessed at biologic initiation and at 6 months.
View Article and Find Full Text PDFIntroduction: Guselkumab is approved for the treatment of both moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in the USA. However, little is known about patients initiating guselkumab in a real-world setting. The objective of this study was to describe baseline characteristics among patients with plaque psoriasis who initiated guselkumab at or after enrollment in CorEvitas' Psoriasis Registry.
View Article and Find Full Text PDFPustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Dermatol Ther (Heidelb)
December 2021
Article Synopsis
- * Diagnosis can be difficult due to its rarity and the lack of established, evidence-based treatments, often leading to management strategies borrowing from standard plaque psoriasis therapies.
- * Recent advances in understanding its causes have opened the door for new treatment options, particularly biologic therapies, with promising results from targeted therapies like spesolimab that inhibit the IL-36 pathway.
Background: Psoriasis is associated with comorbid systemic metabolic disease.
Objective: To assess possible associations of comorbid obesity, history of diabetes, hypertension, and hyperlipidemia with response to biologic treatment at 6 months among patients in CorEvitas' Psoriasis Registry.
Methods: Participants included 2924 patients initiating biologic therapy (tumour necrosis factor inhibitors [TNFi], interleukin [IL]-17i, IL-12/23i, or IL-23i) with baseline and 6-month follow-up visits available.